Suppl. Table 1. Clinical data of major JIA categories documented in the NPRD
* Number of patients who had this item documented at study inclusion. ** Mean cJADAS10 throughout study documentation (until uveitis onset, if applicable).
RF+ polyarthritis: rheumatoid factor-positive polyarthritis; RF- polyarthritis: rheumatoid factor-negative polyarthritis; pers: persistent; ext: extended; JPsA: juvenile psoriasis arthritis; ANA: antinuclear antibodies; HLA-B27: Human Leukocyte Antigen-B27; cJADAS10: Juvenile Arthritis Disease Activity Score 10; DMARD disease modifying antirheumatic drugs; csDMARD conventional-synthetic DMARD; bDMARD biological DMARD

	RF+ polyarthritis	RF- polyarthritis	Oligoarthritis, pers.	Oligoarthritis, ext.	JPsA	ERA
Number of patients	515	3871	11189	1357	1862	3778
Female sex [n (%)]	438 (85.0)	2845 (73.5)	7427 (66.4)	1062 (78.3)	1183 (63.5)	1384 (36.6)
Age at study inclusion [y ± SD]	14.01 ± 3.57	11.41 ± 4.74	8.93 ± 4.60	10.33 ± 4.90	12.10 ± 4.47	13.41 ± 3.14
Age at arthritis diagnosis [y ± SD]	11.58 ± 3.75	8.37 ± 4.68	6.38 ± 4.22	5.30 ± 4.14	9.03 ± 4.53	10.96 ± 3.37
Age at uveitis diagnosis [y ± SD]	6.45 ± 6.82	6.64 ± 4.09	5.34 ± 2.92	4.84 ± 3.07	8.35 ± 4.79	11.47 ± 3.87
Age at first uveitis study documentation [y ± SD]	12.47 ± 5.50	9.43 ± 5.28	8.18 ± 4.37	9.23 ± 5.12	11.95 ± 5.64	14.15 ± 3.95
Patients with uveitis [n (%)]	12 (2.3)	277 (7.2)	1599 (14.3)	302 (22.3)	122 (6.6)	280 (7.4)
JIA disease duration at study inclusion [y ± SD]	2.42 ± 2.83	3.03 ± 3.56	2.54 ± 3.12	5.06 ± 4.48	3.05 ± 3.64	2.45 ± 2.68
Uveitis disease duration at study inclusion [y ± SD]	10.31 ± 8.35	1.56 ± 3.81	2.11 ± 3.97	4.30 ± 4.78	3.28 ± 4.67	1.40 ± 2.57
ANA positive [%] (n)*	37.5 (395)	32.9 (2906)	42.6 (8558)	51.5 (1004)	26.7 (1296)	18.1 (2842)
HLA-B27 positive [%] (n)*	8.9 (424)	8.3 (3071)	7.7 (8669)	9.5 (1114)	13.4 (1539)	58.8 (3510)
Mean cJADAS10**	8.95 ± 6.49	8.03 ± 6.21	4.38 ± 3.54	6.59 ± 5.11	5.52 ± 4.70	5.53 ± 4.33

	Variable	HR	CI	p
			PsA_1 group	
Laboratory parameters	HLA-B27 positivity	2.194	[0.925, 5.203]	0.075
	ANA positivity	2.192	[0.915, 5.250]	0.078
Clinical characteristics	age at PsA onset	0.878	[0.809, 0.954]	0.002
	male sex	0.906	[0.421, 1.949]	0.800
	HAQ score	1.206	[0.588, 2.474]	0.609
	cJADAS10 score	1.066	[0.979, 1.161]	0.139
	PGA (NRS)	1.239	[1.053, 1.458]	0.010
	ESR	1.036	[1.014, 1.059]	0.002
	Presence of psoriasis	0.516	[0.167, 1.600]	0.252
	Duration of PsA prior to baseline	0.195	[0.050, 0.753]	0.018
Systemic treatment	NSAID (treatment prior to baseline)	0.346	[0.117, 1.021]	0.055
	Corticosteroids (irrespective of dosage; treatment prior to baseline)	2.990	[1.392, 6.421]	0.005
	Low dose oral corticosteroids (treatment prior to baseline)	2.099	[0.901, 4.890]	0.086
	High dose oral corticosteroids (treatment prior to baseline)	3.728	[1.484, 9.368]	0.005
	Steroid pulse therapy (treatment prior to baseline)	3.237	[1.108, 9.461]	0.032
csDMARDs	csDMARDs (irrespective of drug; treatment prior to baseline)	2.685	[1.069, 6.749]	0.036
	Hydroxychloroquine (treatment prior to baseline)	0.000	[0.000, Inf]	0.997
	Sulfasalazin (treatment prior to baseline)	0.640	[0.087, 4.728]	0.662
	Methotrexate (treatment prior to baseline)	2.261	[0.941, 5.435]	0.068
	Azathioprine (treatment prior to baseline)	0.000	[0.000, Inf]	0.998
	Cyclosporine A (treatment prior to baseline)	NA	[NA, NA]	NA
	Leflunomide (treatment prior to baseline)	0.000	[0.000, Inf]	0.998
bDMARDs	bDMARDs (irrespective of drug; treatment prior to baseline)	1.270	[0.476, 3.384]	0.633
	Anti-TNF (any drug; treatment prior to baseline)	NA	[NA, NA]	NA
	Etanercept (treatment prior to baseline)	1.550	[0.572, 4.202]	0.389
	Adalimumab (treatment prior to baseline)	0.000	[0.000, Inf]	0.998
	Abatacept (treatment prior to baseline)	0.000	[0.000, Inf]	0.998
	Tocilizumab (treatment prior to baseline)	NA	[NA, NA]	NA
	Canakinumab (treatment prior to baseline)	NA	[NA, NA]	NA
	Other bDMARDs (treatment prior to baseline)	NA	[NA, NA]	NA
	NSAID only (irrespective of drug; treatment prior to baseline)	0.826	[0.332, 2.056]	0.681
	NSAID / Corticosteroids only (irrespective of drug; treatment prior to baseline)	4.034	[1.879, 8.661]	<0.001
	NSAID / Corticosteroids / csDMARDs only (irrespective of drug; treatment prior to baseline)	2.783	[1.107, 6.999]	0.030
	NSAID / Corticosteroids / bDMARDs only (irrespective of drug; treatment prior to baseline)	0.000	[0.000, Inf]	0.997
	combined DMARD therapy (irrespective of drug; treatment prior to baseline)	2.019	[0.641, 6.362]	0.230

Supplementary Material

The Journal of Rheumatology is not responsible or liable for the content of the supplementary material, which has been supplied by the author(s).

J Rheumatol

Suppl. Table 2. Correlates for development of uveitis in the PsA_1 group: Results of univariable Cox regression analysis

ANA: antinuclear antibodies; HLA-B27: Human Leukocyte Antigen-B27; PsA: juvenile psoriasis arthritis; HAQ: health assessment questionnaire; cJADAS10: Juvenile Arthritis Disease Activity Score 10; PGA (NRS): physician's global assessment (numeric rating scale); ESR: erythrocyte sedimentation rate; NSAID: non-steroidal anti-inflammatory drugs; low dose steroids: dosage below 0.1mg/kg bodyweight; high dose steroids: dosage of 0.1mg/kg bodyweight or higher; DMARD disease modifying antirheumatic drugs; csDMARD conventional-synthetic DMARD; bDMARD biological DMARD